STAT | Reporting from the frontiers of health and medicine 中文 关注 STAT+：中国致命基因编辑试验引发伦理与监管质疑 赛诺菲胰岛素笔供应短缺，多肽化合物迎来利好，以及来自《The Readout》的更多生物技术新闻 STAT+: Fatal gene-editing trial in China raises ethics and oversight questions statnews.com
